Market capitalization | $228.92m |
Enterprise Value | $-203.74m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.95 |
P/B ratio (TTM) P/B ratio | 0.61 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-142.26m |
Free Cash Flow (TTM) Free Cash Flow | $-104.51m |
Cash position | $434.09m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
8 Analysts have issued a Olema Pharmaceuticals Inc forecast:
8 Analysts have issued a Olema Pharmaceuticals Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.39 -0.39 |
62%
62%
|
|
EBITDA | -142 -142 |
37%
37%
|
EBIT (Operating Income) EBIT | -142 -142 |
36%
36%
|
Net Profit | -129 -129 |
34%
34%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
Head office | United States |
CEO | Sean Bohen |
Employees | 96 |
Founded | 2006 |
Website | www.olema.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.